These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1853156)

  • 1. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.
    Almer S; Norlander B; Ström M; Osterwald H
    Scand J Gastroenterol; 1991 Mar; 26(3):327-35. PubMed ID: 1853156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema.
    Gionchetti P; Belluzzi A; Campieri M; Torresan F; Tabanelli GM; Brignola C; Miglioli M; Barbara L
    Methods Find Exp Clin Pharmacol; 1988 Oct; 10(10):667-9. PubMed ID: 3236941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1989 Aug; 3(4):333-42. PubMed ID: 2518847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.
    Campieri M; Lanfranchi GA; Boschi S; Brignola C; Bazzocchi G; Gionchetti P; Minguzzi MR; Belluzzi A; Labò G
    Gut; 1985 Apr; 26(4):400-5. PubMed ID: 3979912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results.
    Guarino J; Chatzinoff M; Berk T; Friedman LS
    Am J Gastroenterol; 1987 Aug; 82(8):732-7. PubMed ID: 3496786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrograde distribution of a new 5-aminosalicylic acid enema in patients with ulcerative colitis.
    Almer S; Ekberg S; Ström M
    Gastroenterol Clin Biol; 1992; 16(6-7):564-8. PubMed ID: 1526419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G; Florholmen J
    Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
    Karamanolis DG; Papatheodoridis GV; Xourgias V
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern.
    Bondesen S; Nielsen OH; Jacobsen O; Rasmussen SN; Hansen SH; Halskov S; Binder V; Hvidberg EF
    Scand J Gastroenterol; 1984 Jul; 19(5):677-82. PubMed ID: 6382570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesalamine in ulcerative colitis.
    Fitzgerald JM; Marsh TD
    DICP; 1991 Feb; 25(2):140-5. PubMed ID: 1676200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
    Klotz U; Maier KE
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):46S-50S. PubMed ID: 3319458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
    Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
    Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis.
    Campieri M; Corbelli C; Gionchetti P; Brignola C; Belluzzi A; Di Febo G; Zagni P; Brunetti G; Miglioli M; Barbara L
    Dig Dis Sci; 1992 Dec; 37(12):1890-7. PubMed ID: 1473437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions.
    Jacobsen BA; Abildgaard K; Rasmussen HH; Christensen LA; Fallingborg J; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1991 Apr; 26(4):374-8. PubMed ID: 2034991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema.
    Campieri M; Paoluzi P; D'Albasio G; Brunetti G; Pera A; Barbara L
    Dig Dis Sci; 1993 Oct; 38(10):1843-50. PubMed ID: 8404405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.
    Campieri M; Gionchetti P; Belluzzi A; Brignola C; Tampieri M; Iannone P; Miglioli M; Barbara L
    Gut; 1991 Aug; 32(8):929-31. PubMed ID: 1885075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation.
    Gionchetti P; Campieri M; Venturi A; Rizzello F; Ferretti M; Brignola C; Miglioli M
    Aliment Pharmacol Ther; 1996 Aug; 10(4):601-5. PubMed ID: 8853765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
    Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
    Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.